Clinical Trials Logo

Clinical Trial Summary

The introduction of inhaled medication as the primary treatment for asthma has led to substantial improvements in asthma control [1, 2]. However, uncontrolled asthma is still common and represents a considerable burden to patients and society [3, 4]. An important reason for poor asthma control and consequently, increased healthcare expenditure is suboptimal adherence to the prescribed regimen [5-7].

Real-world market research study in hospitals across China reported that physicians perceived that only 23% of patients were fully compliant with their medication regime (77% non-adherent), compared to 55% in the European Union and 63% in the US [AZ internal document]. The physician reported rate of full adherence was lower than the patient-reported rate (38%). Poor patient adherence was the challenge most frequently mentioned (by 41% of physicians) when treating an asthma.[8]

However

There is some evidence on the drivers of patient behaviour around low adherence but more depth research is needed

There is little evidence on variation of determinants of asthma inhaled treatment across different age of group

Our research aims to address above data gap Mean while this research can guide the development of new module on Red Scarf patient education program.


Clinical Trial Description

Study site(s) and number of subjects planned 8 level-3 hospitals across West China will participate in this study. 40 not well controlled asthma patients will participate the structured interview in stage1 and a total number of 300 patients are expected to participate cross sectional survey in stage 2.

Study period Estimated Time CSP approved Oct. 2016 First subject in Jan. 2017 Last subject in Aug. 2017 Database lock Dec. 2017 CSR Mar. 2017

Study design It is study including 2 stage, stage 1 of structured patient interview by investigators, Stage 2 of a multi-center, cross-sectional survey. 40 eligible asthma patients and/or their family supporter will be invited to participate in a one-time face to face structured interview in stage 1. Around 350 eligible asthma patients will be invited to participate in cross sectional survey which all Information and relevant data of their compliance to inhaled treatment therapy and response to measurement of compliance risk factors (determinants explored from stage 1) will be collected according to CRF, and inputted into an on-line electronic questionnaire data capture (EDC) system by site investigator(s), and valid data will be taken into statistical analyses.

Target subject population Stage 1: Asthmatic patients with in adequate asthma control (defined by GINA partly or un-control due to inhaled treatment compliance (physician judgement) Stage 2: Asthmatic patient who visit the outpatient clinic will be interviewed by investigator.

Objectives

Stage 1:

Primary Objective: Outcome Measure:

Non- Assumptive Deep Dive Qualitative Scoping to investigate determinants of poor adherence to ICS treatment through structured interview & taskforce workshop Decide key measures for phase2 survey through steering committee group review. Categorized "risk factors" (patient behavior/belief, social status, medical care availability etc.) which very likely led to poor patient adherence on inhaled treatment adherence in partly or uncontrolled asthma patients

1. Therapy related factors

2. Patient related factors

3. Provider related factors

4. Disease related factors

5. Practice and system related factors

Questionnaire with measures for asthma patient adherence determinants in survey on stage 2

Stage 2:

Primary Objective: Outcome Measure:

To investigate the relationship different risk factors (determinants explored from stage 1) and treatment adherence to further identify top 5 determinants most closely relative to inhalation treatment adherence

Decide key measures for phase2 survey through steering committee group review. Asthma patient compliance level on Inhaled treatment (ICS or ICS/LABA) by using validated MARS-A scale questionnaire below.

Risk factors (determinants explored from stage 1) measurements response from asthma patients

Secondary Objective: Outcome Measure :

Similar objectives on deferent life-stage group of asthma patients. Similar analysis by different life-stage group of patients (18- 30, 31-45,45-60, 60+)

Statistical methods

- All results will be described. In general, the descriptive statistics (number, mean, and median, standard deviation, minimum and maximum) will be presented for continuous variables. The frequency and percentage of subjects at each level or category will be presented for categorical variables. Where appropriate, 95% confidence intervals will be constructed.

- Risk factor analysis will be performed using univariate and multivariate regression model to explore the relationship between risk factors and the compliance level. In addition to multivariate analysis using all variables, a step-wise variable selection can be used. The level of both variable inclusion and exclusion will be set as 0.15. The important variable (s) can be forced in the model if applicable. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02990117
Study type Observational
Source First Affiliated Hospital Xi'an Jiaotong University
Contact
Status Completed
Phase
Start date November 1, 2016
Completion date January 20, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT04435990 - Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites Phase 3
Completed NCT03563521 - Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
Completed NCT03468790 - Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma. Phase 3
Recruiting NCT04898283 - Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. Phase 3
Recruiting NCT03455959 - Lung-Resident Memory Th2 Cells in Asthma N/A
Not yet recruiting NCT05352126 - Effects of Puressentiel Purifying Spray on Asthma Control in Patients With Mild to Moderate Allergy-induced Asthma. N/A
Completed NCT01104012 - Validation of Proteomic Analyses for Allergic Asthma and Rhinitis N/A
Not yet recruiting NCT06027073 - Biologics and Sublingual Immunotherapy Phase 4
Recruiting NCT05720325 - Dupilumab Effects Against Aeroallergen Challenge Phase 2
Completed NCT03112577 - Study of REGN3500 and Dupilumab in Patients With Asthma Phase 1
Recruiting NCT04891237 - Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen Phase 3
Terminated NCT02953106 - Effects of Intranasal Fluticasone Plus Azelastine on Airway Inflammation in Patients With Asthma & Allergic Rhinitis Phase 4
Completed NCT06063044 - Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children
Completed NCT03705325 - Evaluating Asthma Exacerbation-induced Changes in Lung Function With a Home-based Spirometer N/A
Recruiting NCT05478824 - IL13 Signaling in Allergic Asthma
Withdrawn NCT04035109 - Anakinra as a Rescue Treatment for Allergic Inflammation Phase 1/Phase 2
Suspended NCT04109807 - Effects of Low Dose Ozone on Airway Inflammatory Responses in Adults With Asthma - Sedentary Nasal Ozone (Asthma SNOZ) N/A
Recruiting NCT03983603 - Plant Stanol Esters and Preventing Asthma Symptoms N/A
Not yet recruiting NCT05740748 - Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma Phase 2